/
Clinical Considerations in the Management of Metastatic Col Clinical Considerations in the Management of Metastatic Col

Clinical Considerations in the Management of Metastatic Col - PowerPoint Presentation

danika-pritchard
danika-pritchard . @danika-pritchard
Follow
468 views
Uploaded On 2016-05-30

Clinical Considerations in the Management of Metastatic Col - PPT Presentation

Disease Progression Program Goals Introduction Good News Bad News Case 1 Case 1 Initial CT Scan Sigmoid Colorectal Tumor Case 1 Multiple Lung Metastases Case 1 Description cont Case 1 Light Progression in the Liver ID: 341527

references cont progression case cont references case progression line treatment clinical tumor kras lung abbreviations light liver options 102

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Clinical Considerations in the Managemen..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Clinical Considerations in the Management of Metastatic Colorectal Cancer on Disease ProgressionSlide2
Slide3

Program GoalsSlide4

IntroductionSlide5

Good News, Bad NewsSlide6

Case 1Slide7

Case 1: Initial CT Scan: Sigmoid Colorectal TumorSlide8

Case 1: Multiple Lung MetastasesSlide9

Case 1: Description (cont)Slide10
Slide11

Case 1: Light Progression in the Liver Slide12

Case 1: Light Progression in the LungSlide13

Case 1: Significant Progression in the LiverSlide14

Case 1: Significant Progression in the LungSlide15

Progression on First-line Treatment: Second-line Options (KRAS/RASmu Tumor)Slide16

Clinical Considerations: Second-line Treatment OptionsSlide17

Case 2: What If the Patient Is Older? Slide18

Case 3: What If the Tumor Is KRAS/RASwt? Slide19

BRAF Mutation: Clinical Implications Slide20

Third-line Treatment for Unresectable mCRC (KRAS/RASmut) – Choices and ContingenciesSlide21

Eligibility for Third-line Treatment With RegorafenibSlide22

Regorafenib: Maintaining QoLSlide23

TAS-102: An Investigational Cytotoxic AgentSlide24

TAS-102: AEsSlide25

BiomarkersSlide26

AbbreviationsSlide27

Abbreviations (cont)Slide28

ReferencesSlide29

References (cont)Slide30

References (cont)Slide31

References (cont)Slide32

References (cont)Slide33

References (cont)Slide34

References (cont)Slide35

References (cont)Slide36

References (cont)Slide37

References (cont)Slide38

References (cont)